Therapeutic IgE antibodies: Harnessing a macrophage-mediated immune surveillance mechanism against cancer

Cancer Research

Volumn 77, Issue 11, 2017, Pages 2779-2783

  Karagiannis, Sophia N ^a,b   Josephs, Debra H ^a,b,c   Bax, Heather J ^a,b,c   Spicer, James F ^b,c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOLATE RECEPTOR 1; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELLULAR IMMUNITY; DRUG EFFICACY; HUMAN; IMMUNOSURVEILLANCE; LUNG METASTASIS; MACROPHAGE; MACROPHAGE ACTIVATION; MALIGNANT NEOPLASM; MONOCYTE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR REJECTION; TUMOR XENOGRAFT; ANIMAL; CARCINOMA; IMMUNOLOGY; MOUSE; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC SURVEILLANCE; MACROPHAGES; MICE; TUMOR MICROENVIRONMENT;

EID: 85020713632     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-0428     Document Type: Review

References (31)

1. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer 2015;15:361-70.
2. DiLillo DJ, Ravetch JV. Differential fc-receptor engagement drives an antitumor vaccinal effect. Cell 2015;161:1035-45.
3. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell 2016;164:1233-47.
4. Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge. Cancer Res 2015;75:5-10.
5. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell 2015;27:462-72.
6. Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013;38:792-804.
7. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 2013;39:599-610.
8. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
9. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci 2014;105:1-8.
10. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007;13:5784-9.
11. Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006;108:2648-54.
12. Kern DJ, James BR, Blackwell S, Gassner C, Klein C, Weiner GJ. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma 2013;54:2500-5.
13. Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN. IgE immunotherapy: A novel concept with promise for the treatment of cancer. MAbs 2014;6:54-72.
14. Jensen-Jarolim E, Bax HJ, Bianchini R, Capron M, Corrigan C, Castells M, et al. AllergoOncology - the impact of allergy in oncology: EAACI position paper. Allergy 2016. doi: 10.1111/all.13119.
15. Finkelman FD, Urban JF, Jr. The other side of the coin: The protective role of the TH2 cytokines. J Allergy Clin Immunol 2001;107:772-80.
16. Gounni AS, Lamkhioued B, Ochiai K, Tanaka Y, Delaporte E, Capron A, et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994;367:183-6.
17. Vouldoukis I, Mazier D, Moynet D, Thiolat D, Malvy D, Mossalayi MD. IgE mediates killing of intracellular Toxoplasma gondii by human macrophages through CD23-dependent, interleukin-10 sensitive pathway. PLoS One 2011;6:e18289.
18. Gould HJ, Mackay GA, Karagiannis SN, O'Toole CM, Marsh PJ, Daniel BE, et al. Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 1999;29:3527-37.
19. Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, et al. Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol 2003;33:1030-40.
20. Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, et al. IgE-antibody-dependent immunotherapy of solid tumors: Cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007;179:2832-43.
21. Josephs DH, Bax HJ, Dodev T, Georgouli M, Nakamura M, Pellizzari G, et al. Anti-folate receptor-alpha IgE but not IgG recruits macrophages to attack tumors via TNF-alpha/MCP-1 signaling. Cancer Res 2017;77:1127-41.
22. Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S, et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 2010;10:220.
23. Jensen-Jarolim E, Mechtcheriakova D, Pali-Scholl I. The Targets of IgE; allergen-associated and tumor-associated molecular patterns. In: Penichet M, Jensen-Jarolim E, editors. Cancer and IgE. New York, Dordrecht, Heidelberg, London: Springer; 2010. pp. 231-54.
24. Yadav A, Saini V, Arora S. MCP-1: Chemoattractant with a role beyond immunity: A review. Clin Chim Acta 2010;411:1570-9.
25. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, et al. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol 2007;179:3332-41.
26. Moughon DL, He H, Schokrpur S, Jiang ZK, Yaqoob M, David J, et al. Macrophage blockade using CSF1R inhibitors reverses the vascular leakage underlying malignant ascites in late-stage epithelial ovarian cancer. Cancer Res 2015;75:4742-52.
27. Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL. Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov 2013;3:751-60.
28. Smith KJ, Hamza S, Skelton H. Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern. Clin Exp Dermatol 2004;29:505-12.
29. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-6.
30. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005;65:3437-46.
31. Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, et al. CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy. Cancer Res 2015;75:950-62.